• Publications
  • Influence
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
Prevalence rates of different physical illnesses as well as important individual lifestyle choices, side effects of psychotropic treatment and disparities in health care access, utilization and provision that contribute to these poor physical health outcomes are reported.
What does the PANSS mean?
The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations and may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds.
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
This work aimed to update and expand previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder, and found that all antidepressants were more effective than placebo.
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
It is concluded that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds.
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Maintenance treatment with antipsychotic drugs benefits patients with schizophrenia and the advantages of these drugs must be weighed against their side-effects.
Physical illness and schizophrenia: a review of the literature
Objective:  The lifespan of people with schizophrenia is shortened compared to the general population. We reviewed the literature on comorbid physical diseases in schizophrenia to provide a basis for
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of
All of the 4 new drugs are more effective than placebo, but the magnitude of the effect is only moderate, and all new antipsychotics are associated with less frequent use of antiparkinson medication than haloperidol.
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Despite their popularity, pharmacological augmentations of clozapine are not (yet) demonstrated to be superior to placebo.